ERBB2 and neoplasm: Last but not least, in vivo data showed dose-dependent tumor growth reduction by Neratinib in female athymic nude mice, associated with a HER2 phosphorylation decrease (by 84%) 1h after oral dose of 40 mg/kg of Neratinib [38].